Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 1 Interventional

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT06179069

Public ClinicalTrials.gov record NCT06179069. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 4:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Participants With Small Cell Lung Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer

Study identification

NCT ID
NCT06179069
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
Zai Lab (Shanghai) Co., Ltd.
Industry
Enrollment
339 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 23, 2024 (Actual)
Primary completion
May 30, 2027 (Estimated)
Completion
Jul 31, 2027 (Estimated)
Last update posted
Aug 21, 2026

2024 – 2027

United States locations

U.S. sites
11
U.S. states
11
U.S. cities
11
Facility City State ZIP Site status
City of Hope Duarte California 91010 Withdrawn
Yale Cancer Center New Haven Connecticut 06519 Recruiting
Sarah Cannon Research Institute Sarasota Florida 34232 Recruiting
Barbara Ann Karmanos Cancer Institute Detroit Michigan 48201 Recruiting
Hackensack University Medical Center Hackensack New Jersey 07601 Recruiting
Roswell Park Comprehensive Cancer Center Buffalo New York 14263 Recruiting
Duke University Durham North Carolina 27710 Recruiting
University Hospitals Cleveland Medical Center Cleveland Ohio 44106 Recruiting
University of Pittsburgh Hillman Cancer Center Pittsburgh Pennsylvania 15232 Recruiting
Medical University of South Carolina Charleston South Carolina 29425 Recruiting
NEXT Virginia Fairfax Virginia 22031 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06179069, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 21, 2026 · Synced Sep 30, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06179069 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →